All News

Pembrolizumab is an anti-PD-1 therapy that works by increasing the ability of the immune system to detect and fight tumor cells.

Although the COVID-19 pandemic saw the rapid hemorrhaging of women from careers in science and medicine, research shows the toxicity experienced by women may be structural in nature.

Trial court denial of claim Is pursued on appeal based on alleged error by judge when granting summary judgment.

Unlike the 2022 simplification updates for the hepatitis B and pneumococcal vaccine recommendations, ACIP’s recommendations for patient eligibility for zoster vaccination have become more complicated this year.

The Advisory Committee on Immunization Practices and CDC have prioritized making HBV vaccination recommendations simpler to ease the vaccination process for immunizers and to decrease barriers.

Current development efforts in IVIG are focused on new routes of administration for immunoglobulin that can overcome the limitations of intramuscular administration.

Fentanyl citrate (Actiq) is an opioid agonist indicated for the management of breakthrough pain in cancer patients.

Lung Support Formula is comprised of natural extracts to help promote lung health.

The step-up dosing approach with glofitamab in a phase 1 trial enabled researchers to minimize cytokine release syndrome while maximizing outcomes.

Many health care systems are turning to biosimilars to provide clinical outcomes that are similar to those provided by reference products, but at a reduced cost.

Jeff Betcher, BSPharm, MBA, director of pharmacy at Mayo Clinic in Arizona, discusses how automated chemotherapy dose rounding can help decrease drug waste and cost.

As best practices are established throughout the specialty pharmacy’s entire network, better patient outcomes become possible.

Expert notes that any unease around the use of radiopharmaceuticals is just due to a lack of familiarity with the field.

Training pharmacy technicians to evaluate tasks such as appropriate site of care and plan benefits can reduce the workload for the pharmacist.

Tina Saleh, PharmD, PGY1 specialty pharmacy resident at the University of Illinois Hospital and Health Science System, discusses how oral anticancer agents differ from infusions and how pharmacists can improve tolerability for patients.

Certain areas of chapters written by US Pharmacopeia have evolved since being made official and have become standard best practices today.

Case highlights the need to stop, listen, and investigate when patients or parents express a safety concern.

Lyrica is indicated for neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, spinal cord injury nerve pain, and pain after shingles in adult patients.

Better Nail is an anti-fungal product for fungus under and around the nails.

Angela Livingood, PharmD, MHA, BCGP, CPHQ, diversion specialist at Novant Health, discusses what drug diversion is and why it is important for pharmacists to be aware of it.

Brooke Looney, PharmD, certified specialty pharmacist in the Oncology Clinic at Vanderbilt Specialty Pharmacy, discusses medication changes and adverse events for patients starting encorafenib and binimetinib.

Shields Health Solutions poster presentations highlight a comprehensive approach to specialty patient care and successful results from an expanded offering of instructional programs.

Nicholas Robert, MD, chief medical officer at Ontada, discussed disparities in biomarker testing and how they are being addressed.

New recommendations provide some harmonization to make it easier for clinicians to lower the barriers to assessing and identifying eligible patients for the pneumococcal vaccine.

Connection with others and staying on top of your mental well-being are just as important as physical health.

Early intervention, prudent use of antibiotics can help patients treat condition, speed recovery.

COVID-19 vaccine recommendations have parallel tracks for adults and parallel tracks for children broken down into whether an individual is immunocompromised.

Baricitinib (Olumiant; Eli Lilly and Company) is the first systemic treatment to be approved by the FDA for severe alopecia areata, which affects an estimated 300,000 patients in the United States.